Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:

Description

The latest Pulmonary Arterial Hypertension Market report from Fairfield Market Research reveals global sales reached US$7.9 billion in 2024. Projected to grow at a rate of 8% from 2024 to 2031, the market is expected to reach US$13.2 billion by 2031. The Prostacyclin and Prostacyclin Analogs segment is expected to exhibit the highest revenue growth rate during the period from 2024 to 2031.

The market is expected to experience significant growth in the endothelin receptor antagonist segment from 2024 to 2031. These antagonists are commonly prescribed to address various aspects of pulmonary arterial hypertension (PAH), including heart and lung damage, slowing down PAH progression, and dilating blood vessels.

Clinical studies have demonstrated that individuals with pulmonary arterial hypertension tend to produce excessive endothelin, contributing to hypertension. Consequently, doctors often recommend endothelin receptor antagonists to reduce endothelin levels in the blood vessels. Furthermore, the growing interest in research and development related to endothelin receptor antagonists is expected to further fuel the segment's growth. Research has also highlighted additional therapeutic benefits associated with targeting the endothelin receptor, particularly in the context of pulmonary arterial hypertension treatment.

Insights on Prostacyclin and Prostacyclin Analogs

The Prostacyclin and Prostacyclin Analogs segment are anticipated to exhibit the highest CAGR rate from 2024 to 2031. It is estimated that new cases of pulmonary hypertension occur in one to two individuals per million in the United States annually, according to the National Organization for Rare Disorders. A similar rate is expected in Europe. Pulmonary hypertension can affect individuals of all ages and becomes more common as they age. The rapid increase in its prevalence is attributed to lifestyle changes, including reduced physical activity and increased consumption of alcohol and tobacco, both of which elevate the risk of hypertension and high blood pressure.

Market Dominance of Oral Route of Administration

The Oral Route of Administration accounted for approximately 60% of the pulmonary arterial hypertension market share in 2024. Oral medications for PAH treatment include Letairis, Opsumit, Adcirca, and Revatio. Several factors contribute to the preference for oral drug administration, including patient safety, high effectiveness, and rapid drug delivery.

Region-wise Insights

North America, particularly the United States, is poised to provide the most substantial opportunity in the Pulmonary Arterial Hypertension market. The dominant position is attributed to the well-established healthcare infrastructure, facilitating access to advanced treatments. Factors such as increased awareness, efficient diagnosis rates, and robust government support contribute significantly to market growth. The region benefits from the presence of major competitors and a well-structured reimbursement system, further fueling the demand for advanced medical services in Pulmonary Arterial Hypertension.

Country-wise Insights

U.S. Market Analysis

The United States is expected to hold the largest market share by the end of 2031, significantly contributing to market growth. Pulmonary Arterial Hypertension (PAH) is considered a rare condition in the U.S., with a yearly diagnosis of around 500 - 1,000 new cases. The utilization of PAH extends beyond its traditional applications, encompassing various fields such as vaccine administration, hormonal delivery, cancer therapy, and pain management, which fuels market expansion in the United States.

U.K. Market Analysis

In the United Kingdom, idiopathic pulmonary arterial hypertension affects a substantial population of individuals. Consequently, the country's market is expected to achieve a valuation of considerable value by 2031. The growth trajectory is predicted to be stable, with a consistent CAGR from 2024 to 2031.

Japan Market Analysis

Japan has reported an estimated prevalence rate of pulmonary arterial hypertension at 3.2 cases per 100,000 individuals, with an annual incidence ranging from 70 to 100 cases. Despite these statistics, substantial investments have been directed towards the prevention and management of pulmonary arterial hypertension, contributing to the market's substantial value, as observed in 2021.

South Korea Market Analysis

South Korea demonstrates a consistent and steady market performance for pulmonary arterial hypertension. Statistical data indicates the diagnosis of over 1,307 patients between 2008 and 2016, resulting in an annual incidence rate of 4.84 patients per million individuals. As of 2021, the market in South Korea exhibited a reliable performance and was valued significantly.

Key Companies Profiled

United Therapeutics Corporation
Bayer
Johnson & Johnson
Novartis
Lupin Pharmaceuticals
Viatris Inc.
Sun Pharmaceutical Industries, Inc.
Teva Pharmaceutical Industries Ltd.

Market Segments Covered in Pulmonary Arterial Hypertension Market Analysis

By Drug Class

Endothelin Receptor Antagonists
PDE-5 Inhibitors
Prostacyclin and Prostacyclin Analogs
SGC Stimulators

By Type

Branded
Generics

By Route of Administration

Oral
Intravenous/ Subcutaneous
Inhalational

By Region

North America
Latin America
Europe
APAC
MEA

1. Executive Summary

1.1. Global Pulmonary Arterial Hypertension Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Pulmonary Arterial Hypertension Market Outlook, 2018 - 2031

3.1. Global Pulmonary Arterial Hypertension Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Endothelin Receptor Antagonists
  - 3.1.1.2. PDE-5 Inhibitors
  - 3.1.1.3. Prostacyclin and Prostacyclin Analogs
  - 3.1.1.4. SGC Stimulators
3.2. Global Pulmonary Arterial Hypertension Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Branded
  - 3.2.1.2. Generics
3.3. Global Pulmonary Arterial Hypertension Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Oral
  - 3.3.1.2. Intravenous/ Subcutaneous
  - 3.3.1.3. Inhalational
3.4. Global Pulmonary Arterial Hypertension Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Pulmonary Arterial Hypertension Market Outlook, 2018 - 2031

4.1. North America Pulmonary Arterial Hypertension Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Endothelin Receptor Antagonists
  - 4.1.1.2. PDE-5 Inhibitors
  - 4.1.1.3. Prostacyclin and Prostacyclin Analogs
  - 4.1.1.4. SGC Stimulators
4.2. North America Pulmonary Arterial Hypertension Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Oral
  - 4.2.1.2. Intravenous/ Subcutaneous
  - 4.2.1.3. Inhalational
4.3. North America Pulmonary Arterial Hypertension Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Oral
  - 4.3.1.2. Intravenous/ Subcutaneous
  - 4.3.1.3. Inhalational
- 4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Pulmonary Arterial Hypertension Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.4.1.2. U.S. Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 4.4.1.3. U.S. Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 4.4.1.4. Canada Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.4.1.5. Canada Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 4.4.1.6. Canada Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Pulmonary Arterial Hypertension Market Outlook, 2018 - 2031

5.1. Europe Pulmonary Arterial Hypertension Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Endothelin Receptor Antagonists
  - 5.1.1.2. PDE-5 Inhibitors
  - 5.1.1.3. Prostacyclin and Prostacyclin Analogs
  - 5.1.1.4. SGC Stimulators
5.2. Europe Pulmonary Arterial Hypertension Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Oral
  - 5.2.1.2. Intravenous/ Subcutaneous
  - 5.2.1.3. Inhalational
5.3. Europe Pulmonary Arterial Hypertension Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Oral
  - 5.3.1.2. Intravenous/ Subcutaneous
  - 5.3.1.3. Inhalational
- 5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Pulmonary Arterial Hypertension Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.2. Germany Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.3. Germany Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.4. U.K. Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.5. U.K. Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.6. U.K. Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.7. France Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.8. France Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.9. France Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.10. Italy Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.11. Italy Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.12. Italy Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.13. Turkey Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.14. Turkey Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.15. Turkey Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.16. Russia Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.17. Russia Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.18. Russia Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.19. Rest of Europe Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.20. Rest of Europe Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.21. Rest of Europe Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Pulmonary Arterial Hypertension Market Outlook, 2018 - 2031

6.1. Asia Pacific Pulmonary Arterial Hypertension Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Endothelin Receptor Antagonists
  - 6.1.1.2. PDE-5 Inhibitors
  - 6.1.1.3. Prostacyclin and Prostacyclin Analogs
  - 6.1.1.4. SGC Stimulators
6.2. Asia Pacific Pulmonary Arterial Hypertension Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Oral
  - 6.2.1.2. Intravenous/ Subcutaneous
  - 6.2.1.3. Inhalational
6.3. Asia Pacific Pulmonary Arterial Hypertension Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Oral
  - 6.3.1.2. Intravenous/ Subcutaneous
  - 6.3.1.3. Inhalational
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Pulmonary Arterial Hypertension Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.2. China Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.3. China Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.4. Japan Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.5. Japan Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.6. Japan Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.7. South Korea Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.8. South Korea Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.9. South Korea Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.10. India Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.11. India Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.12. India Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.13. Southeast Asia Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.14. Southeast Asia Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.15. Southeast Asia Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Pulmonary Arterial Hypertension Market Outlook, 2018 - 2031

7.1. Latin America Pulmonary Arterial Hypertension Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Endothelin Receptor Antagonists
  - 7.1.1.2. PDE-5 Inhibitors
  - 7.1.1.3. Prostacyclin and Prostacyclin Analogs
  - 7.1.1.4. SGC Stimulators
7.2. Latin America Pulmonary Arterial Hypertension Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
7.3. Latin America Pulmonary Arterial Hypertension Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Oral
  - 7.3.1.2. Intravenous/ Subcutaneous
  - 7.3.1.3. Inhalational
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Pulmonary Arterial Hypertension Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.4.1.2. Brazil Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.3. Brazil Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 7.4.1.4. Mexico Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.4.1.5. Mexico Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.6. Mexico Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 7.4.1.7. Argentina Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.4.1.8. Argentina Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.9. Argentina Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, 2018 - 2031

8.1. Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Endothelin Receptor Antagonists
  - 8.1.1.2. PDE-5 Inhibitors
  - 8.1.1.3. Prostacyclin and Prostacyclin Analogs
  - 8.1.1.4. SGC Stimulators
8.2. Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Oral
  - 8.2.1.2. Intravenous/ Subcutaneous
  - 8.2.1.3. Inhalational
8.3. Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Oral
  - 8.3.1.2. Intravenous/ Subcutaneous
  - 8.3.1.3. Inhalational
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Pulmonary Arterial Hypertension Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.2. GCC Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.3. GCC Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.4. South Africa Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.5. South Africa Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.6. South Africa Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.7. Egypt Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.8. Egypt Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.9. Egypt Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.10. Nigeria Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.11. Nigeria Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.12. Nigeria Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Pulmonary Arterial Hypertension Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Pulmonary Arterial Hypertension Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Pulmonary Arterial Hypertension Market by Route of Administration, Value (US$ Bn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Product vs Indication Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. United Therapeutics Corporation
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Bayer
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Gilead Sciences, Inc.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Johnson & Johnson
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Viatris Inc.
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. GlaxoSmithKline
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Sandoz Inc. (Novartis)
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Lupin Pharmaceuticals, Inc.
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Sun Pharmaceutical Industries, Inc.
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Teva Pharmaceutical Industries Ltd.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations